ER Positive, HER2 Negative Breast Cancer (DBCOND0060045)

Identifiers

Synonyms

ER-Positive, HER2-Negative Breast Cancer / ER-Positive HER2-Negative Breast Cancer

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04993430	A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer	Dalpiciclib	treatment	1	recruiting
NCT05364255	A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833	Camizestrant	treatment	1	completed
NCT04711252	A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease	Anastrozole Camizestrant Luteinizing hormone Palbociclib	treatment	3	active_not_recruiting
NCT04964934	Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)	Abemaciclib Anastrozole Camizestrant Letrozole Luteinizing hormone Palbociclib Ribociclib	treatment	3	recruiting
NCT01709370	Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women	Letrozole Palbociclib	treatment	2	unknown_status